Uncategorized
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug
While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral factors. The FDA acknowledged the validity of this argument.